Prof. Thomas Müller

Department of Neurology

St. Joseph Hospital Berlin-Weißensee, Germam

Email: th.mueller@alexius.de, thomas.mueller@ruhr-uni-bochum.de

Qualifications

2009 Consultant Neurology/Psychiatry, St Joseph Berlin Tempelhof

2002 Member of the Faculty, Neuroscience of the Ruhr-University of Bochum

1996 Senior physician, University lecturer

Publications (Selected)

1. Shirol, S. B., Saboor, R. A., & Müller, T. (2024). Autoinjectors for Administering Glatiramer Acetate in Relapsing Remitting Multiple Sclerosis in Europe: A Survey of Patient and Nurse Preferences. Degenerative Neurological and Neuromuscular Disease, 131-141.
2. Müller, T. (2024). Evaluating pimavanserin tartrate as a treatment in Parkinson’s disease. Expert Opinion on Pharmacotherapy, 25(15), 1999-2003.
3. Müller, T. (2024). Clinical pharmacokinetics of levodopa and relevant add-on therapies for Parkinson’s disease. Expert Opinion on Drug Metabolism & Toxicology, 1-10.
4. Müller, T., Gerlach, M., Hefner, G., Hiemke, C., Jost, W. H., & Riederer, P. (2024). Therapeutic drug monitoring in Parkinson’s disease. Journal of Neural Transmission, 131(10), 1247-1262.
5. Müller, T., Buhmann, C., Delf, M., Klostermann, F., Kupsch, A., Lipp, A., ... & Südmeyer, M. (2024). Clinicians’ viewpoints on current paradigms of care and research in Parkinson’s disease. Journal of Neural Transmission, 1-8.
6. Müller, T., & Möhr, J. D. (2024). Negative findings from trials with NLY01 or deferiprone for Parkinson's disease. The Lancet Neurology, 23(6), 558-559.
7. Müller, T., Gerlach, M., Hefner, G., Hiemke, C., Jost, W. H., & Riederer, P. (2024). Therapeutic drug monitoring in Parkinson’s disease. Journal of Neural Transmission, 131(10), 1247-1262.
8. Müller, T., & Kuhn, W. (2023). An Indirect Proof for Levodopa‐Induced Vitamin Deficiency in Parkinson's Disease. Movement Disorders, 38(12), 2319-2320.
9. Phokaewvarangkul, O., Bhidayasiri, R., Garcia-Ruiz, P., Odin, P., Riederer, P., & Müller, T. (2023). Homocysteine, vitamin B metabolites, dopamine-substituting compounds, and symptomatology in Parkinson’s disease: clinical and therapeutic considerations. Journal of Neural Transmission, 130(11), 1451-1462.
10. Müller, T., & Kuhn, W. (2023). Effects of Amantadine Sulfate on Motor Impairment and Execution of Motor Sequences in Patients With Parkinson Disease. Clinical neuropharmacology, 46(5), 171-174.
11. Woitalla, D., Buhmann, C., Hilker-Roggendorf, R., Höglinger, G., Koschel, J., Müller, T., & Weise, D. (2023). Role of dopamine agonists in Parkinson's disease therapy. Journal of Neural Transmission, 130(6), 863-873.
12. Müller, T., & Riederer, P. (2024). The vicious circle between homocysteine, methyl group-donating vitamins and chronic levodopa intake in Parkinson’s disease. Journal of Neural Transmission, 131(6), 631-638.
13. Woitalla, D., Buhmann, C., Hilker-Roggendorf, R., Höglinger, G., Koschel, J., Müller, T., & Weise, D. (2023). Role of dopamine agonists in Parkinson's disease therapy. Journal of Neural Transmission, 130(6), 863-873.
14. Müller, T., & Kuhn, W. (2023). Epigenetic drug effects in levodopa-treated patients with Parkinson's disease. Movement disorders: official journal of the Movement Disorder Society, 38(4), 710-711.
15. Müller, T. (2023). The role of istradefylline in the Parkinson’s disease armamentarium. Expert Opinion on Pharmacotherapy, 24(7), 863-871.
16. Müller, T., Riederer, P., & Kuhn, W. (2023). Aminoadamantanes: from treatment of Parkinson’s and Alzheimer’s disease to symptom amelioration of long COVID-19 syndrome?. Expert Review of Clinical Pharmacology, 16(2), 101-107.
17. Müller, T. (2022). Perspective: Is a Closer Interaction between Experimental and Clinical Research Paradigms in Chronic Neurodegeneration, Such as Parkinson’s Disease, Necessary Again?. Cells, 12(1), 157.
18. Müller, T. (2022). Entacapone/tolcapone/opicapone for treating Parkinson’s disease. In NeuroPsychopharmacotherapy (pp. 3309-3326). Cham: Springer International Publishing.
19. Müller, T. (2022). Clinical Aspects of the Pharmacology and Biochemistry of Drugs for the Treatment of Motor Symptoms of Parkinson’s Disease. NeuroPsychopharmacotherapy, 2853-2870.
20. Kuhn, W., Karp, G., & Müller, T. (2022). No vitamin D deficiency in patients with Parkinson’s Disease. Degenerative Neurological and Neuromuscular Disease, 127-131.
21. Müller, T., & Kuhn, W. (2022). Complex motion series performance differs between previously untreated patients with Parkinson’s disease and controls. Journal of Neural Transmission, 129(5), 595-600.
22. Müller, T. (2022). Perspective: cell death mechanisms and early diagnosis as precondition for disease modification in Parkinson’s disease: are we on the right track?. Expert Review of Molecular Diagnostics, 22(4), 403-409.
23. Müller, T., Schlegel, E., Zingler, S., & Thiede, H. M. (2022). Effects of one-day application of levodopa/carbidopa/entacapone versus levodopa/carbidopa/opicapone in Parkinson’s disease patients. Cells, 11(9), 1511.
24. Tönges, L., Buhmann, C., Klebe, S., Klucken, J., Kwon, E. H., Müller, T., ... & Lingor, P. (2022). Blood-based biomarker in Parkinson’s disease: potential for future applications in clinical research and practice. Journal of Neural Transmission, 129(9), 1201-1217.
25. Müller, T. (2022). What are the main considerations when prescribing pharmacotherapy for Parkinson’s disease?. Expert Opinion on Pharmacotherapy, 23(7), 745-750.

Profile Details

https://orcid.org/0000-0002-6799-0753

https://scholar.google.com/citations?user=WTXlxCsAAAAJ&hl=en

https://www.researchgate.net/profile/Thomas-Mueller-21

https://iabnetz.de/en/?author=55493